









市场行情
/
股票
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

200.330USD

+1.920+0.97%

收盘 12/19, 16:00（美东）报价延迟15分钟

3.94B总市值

83.64市盈率 TTM



Ligand Pharmaceuticals Inc

200.330

+1.920+0.97%

概览公司财务分析

概览

公司

财务

分析

关于 Ligand Pharmaceuticals Inc 公司

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Ligand Pharmaceuticals Inc简介



公司代码LGND

公司名称Ligand Pharmaceuticals Inc

上市日期Nov 18, 1992

CEODavis (Todd C)

员工数量68

证券类型Ordinary Share

年结日Nov 18

公司地址555 Heritage Drive, Suite 200

城市JUPITER

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编33458

电话18585507500

网址https://www.ligand.com/

公司代码LGND

上市日期Nov 18, 1992

CEODavis (Todd C)

Ligand Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Jason M. Aryeh

Independent Director

129.19K

+1.60%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

42.97K

-1.08%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-7.77%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

8.26K

-18.40%

Mr. Jason Haas

Independent Director

6.86K

+21.40%

Dr. Martine Zimmermann, Pharm.D.

Independent Director

4.17K

-2.68%

Mr. Todd C. Davis

Chief Executive Officer, Director

名称

名称/职务

职务

持股

持股变动

Mr. Jason M. Aryeh

Independent Director

129.19K

+1.60%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

42.97K

-1.08%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-7.77%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Kyprolis

8.80M

18.48%

Captisol

8.29M

17.40%

Filspari

6.58M

13.81%

Qarziba

5.88M

12.36%

Royalties Other

5.43M

11.41%

其他

12.64M

26.54%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Kyprolis

8.80M

18.48%

Captisol

8.29M

17.40%

Filspari

6.58M

13.81%

Qarziba

5.88M

12.36%

Royalties Other

5.43M

11.41%

其他

12.64M

26.54%

股东统计

更新时间: 11月20日周四

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.35%

The Vanguard Group, Inc.

10.53%

Janus Henderson Investors

5.30%

Nomura Investment Management Business Trust

3.82%

State Street Investment Management (US)

3.81%

其他

63.21%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.35%

The Vanguard Group, Inc.

10.53%

Janus Henderson Investors

5.30%

Nomura Investment Management Business Trust

3.82%

State Street Investment Management (US)

3.81%

其他

63.21%

股东类型

持股股东

占比

Investment Advisor

59.79%

Investment Advisor/Hedge Fund

39.05%

Research Firm

3.68%

Individual Investor

2.27%

Pension Fund

1.68%

Bank and Trust

1.63%

Hedge Fund

0.72%

Sovereign Wealth Fund

0.10%

Venture Capital

0.04%

机构持股



更新时间: 10月5日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q3

541

20.07M

102.40%

-232.93K

2025Q2

535

19.71M

102.13%

-738.05K

2025Q1

554

19.82M

102.82%

-711.89K

2024Q4

546

19.28M

100.16%

-1.51M

2024Q3

543

19.17M

104.83%

-583.22K

2024Q2

527

18.31M

101.74%

-865.78K

2024Q1

520

17.60M

99.35%

-393.03K

2023Q4

527

16.97M

97.29%

-861.76K

2023Q3

515

17.24M

99.38%

-910.17K

2023Q2

526

17.09M

98.94%

-1.02M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.65M

13.55%

-19.35K

-0.72%

Jun 30, 2025

The Vanguard Group, Inc.

2.08M

10.64%

+33.19K

+1.62%

Jun 30, 2025

Janus Henderson Investors

1.06M

5.41%

+33.19K

+3.23%

Jun 30, 2025

Nomura Investment Management Business Trust

926.55K

4.73%

+20.33K

+2.24%

Jun 30, 2025

State Street Investment Management (US)

749.75K

3.83%

+22.63K

+3.11%

Jun 30, 2025

Congress Asset Management Company, LLP

647.94K

3.31%

+5.23K

+0.81%

Jun 30, 2025

Chicago Capital, LLC

571.83K

2.92%

+17.31K

+3.12%

Jun 30, 2025

Stephens Investment Management Group, LLC

604.81K

3.09%

-2.41K

-0.40%

Jun 30, 2025

MFS Investment Management

339.74K

1.73%

+61.95K

+22.30%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

704.52K

3.6%

-40.41K

-5.42%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Franklin Genomic Advancements ETF

4.21%

Invesco Pharmaceuticals ETF

3.2%

State Street SPDR S&P Pharmaceuticals ETF

3.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.74%

Virtus LifeSci Biotech Products ETF

2.67%

Invesco S&P SmallCap Health Care ETF

2.3%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

1.64%

iShares U.S. Pharmaceuticals ETF

1.38%

First Trust Multi-Manager Small Cap Opportunities ETF

1.09%

Franklin Genomic Advancements ETF

占比4.21%

Invesco Pharmaceuticals ETF

占比3.2%

State Street SPDR S&P Pharmaceuticals ETF

占比3.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比2.74%

Virtus LifeSci Biotech Products ETF

占比2.67%

Invesco S&P SmallCap Health Care ETF

占比2.3%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.64%

iShares U.S. Pharmaceuticals ETF

占比1.38%

First Trust Multi-Manager Small Cap Opportunities ETF

占比1.09%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Ligand Pharmaceuticals Inc的前五大股东是谁？



Ligand Pharmaceuticals Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：2.65M，占总股份比例：13.55%。
The Vanguard Group, Inc.持有股份：2.08M，占总股份比例：10.64%。
Janus Henderson Investors持有股份：1.06M，占总股份比例：5.41%。
Nomura Investment Management Business Trust持有股份：926.55K，占总股份比例：4.73%。
State Street Investment Management (US)持有股份：749.75K，占总股份比例：3.83%。